

Company name: KYORIN Holdings, Inc.

Representative: Masahiro Yamashita

Representative Director, President

(Securities Code: 4569, TSE 1st Sec.)

**Announcement regarding transfer of “Pekiron Cream 0.5%”  
topical antifungal medication business.**

TOKYO, October 9, 2012 – KYORIN Pharmaceutical Co., Ltd. (Head office: Chiyoda-ku, Tokyo, President: Masahiro Yamashita), a wholly owned subsidiary of KYORIN Holdings, Inc. and Galderma SA (Lausanne, Switzerland, CEO: Humberto C. Antunes) have concluded an asset transfer agreement for Pekiron cream 0.5% (INN : Amorolfine Hydrochloride), a topical anti-fungal prescription drug. Kyorin Pharmaceutical Co., Ltd. obtained the marketing authorization license for the product in October 1993 and launched it in February 1994. In March 2002, Kyorin Pharmaceutical Co., Ltd. concluded a sales right transfer agreement with Galderma K.K., Galderma SA's subsidiary in Japan. The recent agreement signed by the two companies now transfers all Pekiron assets to Galderma SA. Pekiron cream 0.5% is currently co-marketed with Sato Seiyaku, and this co-market will continue after the business transfer to Galderma SA.

Kyorin Pharmaceutical Co., Ltd. has been pursuing the Franchise Customer Strategy under which it focuses of the respiratory, otolaryngology and urology fields. With the transfer of the business, we believe it can further focus on the strategic fields.

With this transfer, Galderma SA, a global leading pharmaceutical company specializing in the research, development and marketing of innovative medical solutions in dermatology consolidates its position in the mycoses market and maximizes the amorolfine franchise.

1. Dates of transfer

- February 1, 2013

2. Financial impact on Kyorin

- Expected financial impact is minimal on the consolidated financial results for period end in March 2013.

**For reference : About Galderma**

Galderma is a global company founded in 1981 committed to delivering innovative medical solutions to meet the dermatological needs of people throughout their lifetime while serving healthcare professionals around the world. The company has more than 4,000 employees and 31 wholly-owned affiliates, of which Galderma K.K. in Japan was founded in 1996. Galderma's extensive product portfolio is available in 70 countries and treats a range of dermatological conditions including: acne, rosacea, onychomycosis, psoriasis & steroid-responsive dermatoses, pigmentary disorders, skin cancer and medical solutions for skin senescence.

With approximately 19% of revenues invested each year to discover and develop new products and access innovative technologies, the company is one of the world's leading investors in dermatology R&D.

Strategic global brands include Epiduo, Oracea, Clobex, Differin, Rozex/MetroGel, Silkis/Vectical, Tri-Luma, Loceryl, Cetaphil, Metvix, Azzalure, Dysport\*, Restylane and Emervel.

\*Dysport is a trademark of Ipsen

For more information about Galderma, please visit: [www.galderma.com](http://www.galderma.com)